Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
July 2014

Do Children Taking SGAs Get Metabolic Monitoring?
Careful monitoring of adverse effects of psychotropic drugs in general and second-generation antipsychotics in particular falls below recommended standards for children and adolescents.

A New Treatment for Parkinson Disease Psychosis
In a placebo-controlled study of patients with Parkinson disease and psychosis, the 5-HT-2A receptor inverse agonist pimavanserin improved psychotic symptoms and did not worsen motor signs.

Ramelteon (Rozerem) to Prevent Delirium?
Preliminary results from using the melatonin-receptor agonist ramelteon (Rozerem) in hospitalized patients to prevent delirium are encouraging.

In Brief
Starting Dose of Eszopiclone Lowered to Avoid Next-Day Impairment; Study Examines Determinants of Antipsychotic Treatment Response

Anxiolytics, Hypnotics, and Mortality Risk
In a retrospective cohort study, a significant association was found between the use of anxiolytic and hypnotic drugs and an increased risk of death.

Affiliated Links

The Journal of Clinical Psychiatry

The University of Arizona Health Sciences Center- Department of Psychiatry

American Academy of Child and Adolescent Psychiatry

American Association of Suicidology

American Psychiatric Association

American Society for Adolescent Psychiatry

American Society of Addiction Medicine

American Society of Clinical Psychopharmacology

Autism Society of America

Depression and Bipolar Support Alliance (DBSA)

National Alliance for Research on Schizophrenia and Depression (NARSAD)

National Alliance for the Mentally Ill

National Association of Alcoholism and Drug Abuse Counselors

National Institute of Mental Health

National Mental Health Association